DOI QR코드

DOI QR Code

General and Genetic Toxicology of Enzyme-Treated Ginseng Extract - Toxicology of Ginseng Rh2+ -

  • Jeong, Mi-Kyung (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Cho, Chong-Kwan (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Yoo, Hwa-Seung (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University)
  • Received : 2016.07.06
  • Accepted : 2016.08.08
  • Published : 2016.09.30

Abstract

Objectives: Ginseng Rh2+ is enzyme-treated ginseng extract containing high amounts of converted ginsenosides, such as compound k, Rh2, Rg3, which have potent anticancer activity. We conducted general and genetic toxicity tests to evaluate the safety of ginseng Rh2+. Methods: An acute oral toxicity test was performed at a high-level dose of 4,000 mg/kg/day in Sprague-Dawley (SD) rats. A 14-day range-finding study was also conducted to set dose levels for the 90-day study. A subchronic 90-day toxicity study was performed at dose levels of 1,000 and 2,000 mg/kg/day to investigate the no-observed-adverse-effect level (NOAEL) of ginseng Rh2+ and target organs. To identify the mutagenic potential of ginseng Rh2+, we conducted a bacterial reverse mutation test (Ames test) using amino-acid-requiring strains of Salmonella typhimurium and Escherichia coli (E. coli), a chromosome aberration test with Chinese hamster lung (CHL) cells, and an in vivo micronucleus test using ICR mice bone marrow as recommended by the Korean Ministry of Food and Drug Safety. Results: According to the results of the acute oral toxicity study, the approximate lethal dose (ALD) of ginseng Rh2+ was estimated to be higher than 4,000 mg/kg. For the 90-day study, no toxicological effect of ginseng Rh2+ was observed in body-weight changes, food consumption, clinical signs, organ weights, histopathology, ophthalmology, and clinical pathology. The NOAEL of ginseng Rh2+ was established to be 2,000 mg/kg/day, and no target organ was found in this test. In addition, no evidence of mutagenicity was found either on the in vitro genotoxicity tests, including the Ames test and the chromosome aberration test, or on the in vivo in mice bone marrow micronucleus test. Conclusion: On the basis of our findings, ginseng Rh2+ is a non-toxic material with no genotoxicity. We expect that ginseng Rh2+ may be used as a novel adjuvant anticancer agent that is safe for long-term administration.

Acknowledgement

Supported by : MICO Co.

References

  1. Jia L, Zhao Y. Current evaluation of the millennium phytomedicine--ginseng (I): etymology, pharmacognosy, phytochemistry, market and regulations. Curr Med Chem. 2009;16(19):2475-84. https://doi.org/10.2174/092986709788682146
  2. Christensen LP. Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res. 2009;55:1-99.
  3. Qi LW, Wang CZ, Yuan CS. Isolation and analysis of ginseng: advances and challenges. Nat Prod Rep. 2011;28(3):467-95. https://doi.org/10.1039/c0np00057d
  4. Shin BK, Kwon SW, Park JH. Chemical diversity of ginseng saponins from Panax ginseng. J Ginseng Res. 2015;39(4):287-98. https://doi.org/10.1016/j.jgr.2014.12.005
  5. Wang W, Zhao Y, Rayburn ER, Hill DL, Wang H, Zhang R. In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol. 2007;59(5):589-601. https://doi.org/10.1007/s00280-006-0300-z
  6. Wang CZ, Du GJ, Zhang Z, Wen XD, Calway T, Zhen Z, et al. Ginsenoside compound K, not Rb1, possesses potential chemopreventive activities in human colorectal cancer. Int J Oncol. 2012;40(6):1970-6. https://doi.org/10.3892/ijo.2012.1399
  7. Shibata S. Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci. 2001;S16:S28-37.
  8. Jang SI, Lee YW, Cho CK, Yoo HS, Jang JH. Identification of target genes involved in the antiproliferative effect of enzyme-modified ginseng extract in HepG2 hepatocarcinoma cell. Evid Based Complement Alternat Med. 2013;2013:ID502568.
  9. Kim KH, Choi I, Lee YW, Cho CK, Yoo HS, Lee SB, et al. Target genes involved in antiproliferative effect of modified ginseng extracts in lung cancer A549 cells. Acta Biochim Biophys Sin (Shanghai). 2014;46(6):441-9. https://doi.org/10.1093/abbs/gmu025
  10. Hwang JW, Baek YM, Jang IS, Yang KE, Lee DG, Yoon SJ, et al. An enzymatically fortified ginseng extract inhibits proliferation and induces apoptosis of KATO3 human gastric cancer cells via modulation of Bax, mTOR, PKB and $I{\kappa}B{\alpha}$. Mol Med Rep. 2015;11(1):670-6. https://doi.org/10.3892/mmr.2014.2704
  11. Chan PC, Peckham JC, Malarkey DE, Kissling GE, Travlos GS, Fu PP. Two-year toxicity and carcinogenicity studies of Panax ginseng in fischer 344 rats and B6C3F1 mice. Am J Chin Med. 2011;39(4):779-88. https://doi.org/10.1142/S0192415X11009184
  12. Seely D, Dugoua JJ, Perri D, Mills E, Koren G. Safety and efficacy of Panax ginseng during pregnancy and lactation. Can J Clin Pharmacol. 2008;15(1):e87-94.
  13. Park SJ, Lim KH, Noh JH, Jeong EJ, Kim YS, Han BC, et al. Subacute oral toxicity study of Korean red ginseng extract in sprague-dawley rats. Toxicol Res. 2013;29(4):285-92. https://doi.org/10.5487/TR.2013.29.4.285
  14. Schmid W. The micronucleus test. Mutat Res. 1975;31(1):9-15. https://doi.org/10.1016/0165-1161(75)90058-8
  15. Tawab MA, Bahr U, Karas M, Wurglics M, Schubert- Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos. 2003;31(8):1065-71. https://doi.org/10.1124/dmd.31.8.1065
  16. Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci. 2004;95(2):153-7. https://doi.org/10.1254/jphs.FMJ04001X4
  17. Lee SJ, Kim YJ, Kim MG. Changes in the ginsenoside content during the fermentation process using microbial strains. J Ginseng Res. 2015;39(4):392-7. https://doi.org/10.1016/j.jgr.2015.05.005
  18. Quan LH, Kim YJ, Li GH, Choi KT, Yang DC. Microbial transformation of ginsenoside Rb1 to compound K by Lactobacillus paralimentarius. World J Microbiol Biotechnol. 2013;29(6):1001-7. https://doi.org/10.1007/s11274-013-1260-1
  19. Cho SH, Chung KS, Choi JH, Kim DH, Lee KT. Compound K, a metabolite of ginseng saponin, induces apoptosis via caspase-8-dependent pathway in HL-60 human leukemia cells. BMC Cancer. 2009;9:449. https://doi.org/10.1186/1471-2407-9-449
  20. Zheng ZZ, Ming YL, Chen LH, Zheng GH, Liu SS, Chen QX. Compound K-induced apoptosis of human hepatocellular carcinoma MHCC97-H cells in vitro. Oncol Rep. 2014;32(1):325-31. https://doi.org/10.3892/or.2014.3171
  21. Kim AD, Kang KA, Kim HS, Kim DH, Choi YH, Lee SJ, et al. A ginseng metabolite, compound K, induces autophagy and apoptosis via generation of reactive oxygen species and activation of JNK in human colon cancer cells. Cell Death Dis. 2013;4:e750. https://doi.org/10.1038/cddis.2013.273
  22. Hu C, Song G, Zhang B, Liu Z, Chen R, Zhang H, et al. Intestinal metabolite compound K of panaxoside inhibits the growth of gastric carcinoma by augmenting apoptosis via Bid-mediated mitochondrial pathway. J Cell Mol Med. 2012;16(1):96-106. https://doi.org/10.1111/j.1582-4934.2011.01278.x
  23. Kang KA, Piao MJ, Kim KC, Zheng J, Yao CW, Cha JW, et al. Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity. Int J Oncol. 2013;43(6):1907-14. https://doi.org/10.3892/ijo.2013.2129
  24. Zhang Z, Du GJ, Wang CZ, Wen XD, Calway T, Li Z, et al. Compound K, a ginsenoside metabolite, inhibits colon cancer growth via multiple pathways including p53-p21 interactions. Int J Mol Sci. 2013;14(2):2980-95. https://doi.org/10.3390/ijms14022980
  25. Wang CZ, Cai Y, Anderson S, Yuan CS. Ginseng metabolites on cancer chemoprevention: an angiogenesis link?. Diseases. 2015;3(3):193-204. https://doi.org/10.3390/diseases3030193
  26. Yang Z, Zhao T, Liu H, Zhang L. Ginsenoside Rh2 inhibits hepatocellular carcinoma through ${\beta}$-catenin and autophagy. Sci Rep. 2016;6:19383. https://doi.org/10.1038/srep19383
  27. Tang XP, Tang GD, Fang CY, Liang ZH, Zhang LY. Effects of ginsenoside Rh2 on growth and migration of pancreatic cancer cells. World J Gastroenterol. 2013;19(10):1582-92. https://doi.org/10.3748/wjg.v19.i10.1582
  28. Choi S, Kim TW, Singh SV. Ginsenoside Rh2-mediated G1 phase cell cycle arrest in human breast cancer cells is caused by p15 Ink4B and p27 Kip1-dependent inhibition of cyclin-dependent kinases. Pharm Res. 2009;26(10):2280-8. https://doi.org/10.1007/s11095-009-9944-9
  29. Yoon JH, Choi YJ, Lee SG. Ginsenoside Rh1 suppresses matrix metalloproteinase-1 expression through inhibition of activator protein-1 and mitogen-activated protein kinase signaling pathway in human hepatocellular carcinoma cells. Eur J Pharmacol. 2012;679(1-3):24-33. https://doi.org/10.1016/j.ejphar.2012.01.020
  30. Jung JS, Ahn JH, Le TK, Kim DH, Kim HS. Protopanaxatriol ginsenoside Rh1 inhibits the expression of matrix metalloproteinases and the in vitro invasion/migration of human astroglioma cells. Neurochem Int. 2013;63(2):80-6. https://doi.org/10.1016/j.neuint.2013.05.002
  31. Test No. 471: Bacterial Reverse Mutation Test [internet]. France: OECD; 1997. Available from: http://www.oecd-ilibrary.org/environment/test-no-471-bacterialreverse-mutation-test_9789264071247-en.
  32. Chen Q, Tang S, Jin X, Zou J, Chen K, Zhang T, et al. Investigation of the genotoxicity of quinocetone, carbadox and olaquindox in vitro using Vero cells. Food Chem Toxicol. 2009;47(2):328-34. https://doi.org/10.1016/j.fct.2008.11.020
  33. Scheutwinkel-Reich M, vd Hude W. Sister-chromatid exchange in Chinese hamster V79 cells exposed to quindoxin, carbadox and olaquindox. Mutat Res. 1984;139(4):199-202. https://doi.org/10.1016/0165-7992(84)90128-3
  34. Test No. 408: Repeated Dose 90-day Oral Toxicity Study in Rodents [internet]. France: OECD; 1998. Available from: http://www.oecd-ilibrary.org/environment/testno-408-repeated-dose-90-day-oral-toxicity-study-inrodents_9789264070707-en.
  35. Jena GB, Kaul CL, Poduri R. Genotoxicity testing, a regulatory requirement for drug discovery and development: impact of ICH guidelines. Indian J Pharm. 2002;34:86-99.
  36. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482-94. https://doi.org/10.1056/NEJMra0706547
  37. Shumay DM, Maskarinec G, Kakai H, Gotay CC. Why some cancer patients choose complementary and alternative medicine instead of conventional treatment. J Fam Pract. 2001;50(12):1067.
  38. Tian JH, Liu LS, Shi ZM, Zhou ZY, Wang L. A randomized controlled pilot trial of "Feiji Recipe" on quality of life of non-small cell lung cancer patients. Am J Chin Med. 2010;38(1):15-25. https://doi.org/10.1142/S0192415X10007646
  39. Wang CZ, Calway T, Yuan CS. Herbal medicines as adjuvants for cancer therapeutics. Am J Chin Med. 2012;40(4):657-69. https://doi.org/10.1142/S0192415X12500498
  40. Li Y, Zhou T, Ma C, Song W, Zhang J, Yu Z. Ginsenoside metabolite compound K enhances the efficacy of cisplatin in lung cancer cells. J Thorac Dis. 2015;7(3):400-6. https://doi.org/10.3978/j.issn.2072-1439.2015.01.03
  41. Zhang K, Li Y. Effects of ginsenoside compound K combined with cisplatin on the proliferation, apoptosis and epithelial mesenchymal transition in MCF-7 cells of human breast cancer. Pharm Biol. 2016;54(4):561-8. https://doi.org/10.3109/13880209.2015.1101142

Cited by

  1. Ginsenoside Rh2 epigenetically regulates cell-mediated immune pathway to inhibit proliferation of MCF-7 breast cancer cells 2017, https://doi.org/10.1016/j.jgr.2017.05.003